About OliX Pharmaceuticals
OliX Pharmaceuticals is a company based in Suwon (South Korea) founded in 2010. The company has 69 employees as of December 31, 2024. OliX Pharmaceuticals operates in a competitive market with competitors including Avidity Biosciences, Alnylam, Dicerna Pharmaceuticals, Silence Therapeutics and Sirnaomics, among others.
- Headquarter Suwon, South Korea
- Employees 69 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Olix Pharmaceuticals, Inc.
-
Annual Revenue
$3.85 M (USD)-66.73as on Dec 31, 2024
-
Net Profit
-$27.57 M (USD)-112.85as on Dec 31, 2024
-
EBITDA
-$19.18 M (USD)-82.02as on Dec 31, 2024
-
Latest Funding Round
$72.74 M (USD), Post-IPO
Jun 02, 2026
-
Investors
BOLD
& 1 more
-
Employee Count
69
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of OliX Pharmaceuticals
OliX Pharmaceuticals is a publicly listed company on the KRX with ticker symbol 226950 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of OliX Pharmaceuticals
Unlock access to complete
Funding Insights of OliX Pharmaceuticals
Investors in OliX Pharmaceuticals
OliX Pharmaceuticals has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include BOLD and Weiss Asset Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for OliX Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OliX Pharmaceuticals
Investment portfolio details for OliX Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OliX Pharmaceuticals
Detailed financials for OliX Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Olix Pharmaceuticals Comparisons
Peer comparison for OliX Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OliX Pharmaceuticals
OliX Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Alnylam, Dicerna Pharmaceuticals, Silence Therapeutics and Sirnaomics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Drugs are developed using RNA interference technology platform.
|
|
| Locked | Locked | Locked |
RNA therapeutics for hematology and cardiovascular diseases are developed.
|
|
| Locked | Locked | Locked |
RNA-based therapeutics for cancer and fibrosis are developed.
|
|
| Locked | Locked | Locked |
RNAi therapeutics for neurodegenerative diseases are developed using branched siRNA.
|
Detailed competitors of OliX Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Olix Pharmaceuticals
Complete news archive for OliX Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OliX Pharmaceuticals
OliX Pharmaceuticals was founded in 2010 and raised its 1st funding round 16 years after it was founded.
OliX Pharmaceuticals is headquartered in Suwon, South Korea. It is registered at Suwon, Gyeonggi, South Korea.
As of Dec 31, 2024, the latest employee count at OliX Pharmaceuticals is 69.
Annual revenue of OliX Pharmaceuticals is $3.85M as on Dec 31, 2024.
Developer of RNAi therapeutics for dermal, ophthalmic, and pulmonary diseases. Its drug pipeline includes OLX101 for the treatment of Skin Scar (licensed out to Huge Inc.), OLX201 for the treatment of Lung fibrosis, OLX301 for the treatment of Wet AMDRetinal Fibrosis, OLX701 for liver fibrosis. Other products include OLX102 for skin whitening and OLX105 to get rid of wrinkles. The companys technology is based on three types of RNA: Small interfering RNA (siRNA), Asymmetric siRNA (siRNA), and Cell-penetrating asymmetric siRNA (cp-siRNA).
OliX Pharmaceuticals's top competitors include Alnylam, Avidity Biosciences and Silence Therapeutics.
Yes, OliX Pharmaceuticals is publicly traded on KRX under the ticker symbol 226950.
OliX Pharmaceuticals has 2 investors. Key investors include BOLD, and Weiss Asset Management.
The ticker symbol of OliX Pharmaceuticals is 226950 on KRX.